Helix Anesthesia is available now on Google Play — the free tier is permanent, not a trial. Install it →
HelixAnesthesia
Get the app
← All clinical answers

Anesthetic considerations in severe COPD

A perioperative guide for anesthesia providers — what the disease is and how it progresses, induction agent choice, lung-protective ventilation and auto-PEEP, and the phrenic nerve palsy problem with interscalene block.

Published September 27, 2026 · Last reviewed September 26, 2026 · Written by Anastasia Jackson, DNAP, CRNA

Every clinical claim on this page is cited to its source below. How we source clinical content.

The short answer

In severe COPD the enemy is expiratory flow limitation. Everything follows from it: the lung cannot empty, so positive-pressure ventilation stacks breaths into dynamic hyperinflation and auto-PEEP, which raises airway pressures, drops venous return, and threatens barotrauma and hypotension. Build the anesthetic around emptying the lung — low tidal volume, low respiratory rate, and a long expiratory time — and around avoiding bronchospasm. Favor induction and maintenance agents that blunt airway reflexes and bronchodilate (propofol or ketamine for induction, a volatile agent for maintenance), avoid histamine-releasing drugs, ensure full reversal of neuromuscular blockade (sugammadex preferred), and consider extubation onto noninvasive ventilation. For shoulder or upper-limb surgery, remember that a standard interscalene block causes ipsilateral phrenic nerve palsy in nearly all patients and can be poorly tolerated in severe COPD — choose a phrenic-sparing technique or a lower volume, extrafascial injection.

Key takeaways

  • Expiratory flow limitation is the master problem. Loss of elastic recoil, small-airway collapse, and prolonged time constants trap gas at end-expiration, producing dynamic hyperinflation and intrinsic PEEP (auto-PEEP).6,9
  • Auto-PEEP is a hemodynamic problem, not just a mechanical one. It raises intrathoracic pressure, impairs right ventricular filling and increases RV afterload, and predisposes to barotrauma and hypotension.6,9
  • Ventilate to let the lung empty. Low tidal volume (6–8 mL/kg IBW), reduced respiratory rate, prolonged expiratory time, and cautious external PEEP to offset auto-PEEP are the core moves.6,8,9
  • Choose airway-friendly anesthetics. Propofol and ketamine blunt reflex bronchoconstriction on induction; volatile agents (sevoflurane, isoflurane) are bronchodilators for maintenance; avoid thiopental and histamine-releasing drugs.14,15,16,17
  • Full neuromuscular recovery matters. Confirm a train-of-four ratio ≥0.9; sugammadex reversal reduces postoperative pulmonary complications in at-risk patients.7,25,27,28
  • Interscalene block causes near-universal phrenic palsy. Standard-volume interscalene block produces hemidiaphragmatic paralysis in 92–100% of patients after 20 mL, reducing spirometric measures of pulmonary function by 25% to 32%; this can be dangerous in severe COPD.31,39
  • Phrenic-sparing options exist. Low-volume/extrafascial injection, and distal blocks (suprascapular plus infraclavicular/axillary), markedly reduce diaphragmatic paralysis.33,34,35

What COPD is

Chronic obstructive pulmonary disease is a progressive respiratory disease defined by persistent, incompletely reversible airflow limitation arising from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), with chronic airway inflammation.1,2 Tobacco smoking remains the leading risk factor for COPD in high-income countries, accounting for over 70% of cases, whereas in low- and middle-income countries it contributes around 30% to 40% of the burden, and household air pollution from burning wood, animal dung, crop residues, and coal is associated with an increased risk of COPD.1

Two structural lesions drive the physiology relevant to anesthesia:

The inflammatory milieu is neutrophil- and macrophage-predominant, with CD8+ T cells; neutrophilic inflammation correlates with severity of obstruction and rate of FEV1 decline.3,4 As disease advances, inflammation extends beyond the lung, contributing to the cardiovascular, metabolic, and musculoskeletal comorbidities that raise perioperative risk.1,4

This is in the app, with the calculators and the drug library — free tier, no card. Get it →

How COPD progresses and is staged

Airflow limitation is confirmed by post-bronchodilator spirometry showing an FEV1/FVC ratio < 0.70.1 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades severity of airflow obstruction by percent-predicted FEV1 (Figure 2.10 of the 2026 GOLD report):1

GOLD gradePost-bronchodilator FEV1 (% predicted)Descriptor
GOLD 1≥80%Mild
GOLD 250–79%Moderate
GOLD 330–49%Severe
GOLD 4<30%Very severe

GOLD separately assigns patients to groups A, B, or E using symptom burden (mMRC or CAT scores) and exacerbation history, which guides pharmacotherapy but is distinct from the numeric airflow grade.1 Severe and very severe grades (GOLD 3–4) are the population in which the perioperative concerns below become clinically decisive. A low or rapidly declining FEV1 is associated with increased mortality.1

Progression is characterized by an accelerated annual decline in FEV1, increasing dyspnea and exercise limitation, recurrent exacerbations (each associated with faster decline and higher mortality), and eventual chronic respiratory failure and cor pulmonale.1,2,11 Current pharmacotherapy — inhaled bronchodilators, inhaled corticosteroids in selected patients, mucolytics — relieves symptoms and reduces exacerbations but does not clearly halt the underlying loss of lung function.1,2

Why severe COPD raises perioperative risk

Postoperative pulmonary complications (PPCs) — pneumonia, atelectasis, worsening airflow obstruction, and respiratory failure — are as common and consequential as cardiac complications in COPD patients undergoing surgery.1,5 Risk rises with COPD severity, smoking, poor general and nutritional status, age, and obesity, but the surgical site is the single strongest predictor: risk climbs as the incision approaches the diaphragm (upper abdominal and thoracic surgery highest).1,5

Optimize before elective surgery. Surgery should be postponed if an exacerbation is present. Clinically symptomatic patients or those with limited exercise capacity should be treated medically and intensively before surgery, using the same measures established for such patients outside the surgical setting (including bronchodilators and smoking cessation). Comorbid conditions, especially cardiac disease, should be systematically assessed and treated before any major surgical intervention.1

In a retrospective cohort of 419 COPD patients undergoing abdominal surgery, 28.8% experienced a PPC, and PPC was associated with markedly higher 90-day mortality (5.8% vs 1.3%). Three modifiable intraoperative factors independently reduced PPC risk: low tidal volume ventilation, restricted fluid administration, and sugammadex reversal of neuromuscular blockade.7

Induction agent choice

The goals at induction in severe COPD are to blunt airway reflexes, avoid triggering bronchospasm, and maintain hemodynamic stability. The following assumes a non-pregnant adult with severe but stable COPD; confirm doses against institutional protocol and adjust for age, frailty, and hemodynamics.

AgentAirway effectPractical role in severe COPD
PropofolBlunts airway reflexes and attenuates neurally mediated bronchoconstriction;14 produces lower airway resistance after intubation than thiopental or etomidate.15,16Reasonable first choice for the hemodynamically stable patient; watch for hypotension and post-induction cardiovascular instability.12,13
Ketamine (1–2 mg/kg IV)41Attenuates reflex (vagally mediated) bronchoconstriction; also relaxes airway smooth muscle, though the direct effects occur at high concentrations and are unlikely to be of primary clinical relevance; improves gas exchange and dynamic compliance in refractory bronchospasm.14,22Preferred when bronchospasm risk is high or hemodynamics are tenuous; sympathomimetic support of blood pressure. Increases secretions.21,22,23
Etomidate (0.3 mg/kg IV)42Hemodynamically stable but less bronchoprotective than propofol; adrenal suppression for up to ~3 days.12,13Reasonable for the hemodynamically fragile patient, though in critically ill adults available data favor ketamine over etomidate; not chosen for airway protection.12,13
ThiopentalGreater risk of bronchospasm on induction; fails to reduce respiratory system resistance.15,17Best avoided in bronchospastic disease.15,16

In anesthetized sheep, infusion of propofol and ketamine into the bronchial artery caused a dose-dependent attenuation of vagal nerve stimulation–induced bronchoconstriction; the authors concluded that their local bronchoprotective effect is through neurally mediated mechanisms.14 Whichever agent is chosen, ensure an adequate depth of anesthesia before laryngoscopy, since instrumentation of a light airway is a classic bronchospasm trigger.16

Avoid histamine-releasing drugs. Neuromuscular blockers such as atracurium and mivacurium, and opioids such as morphine,24 can cause dose-dependent histamine release and bronchoconstriction; among relaxants, cisatracurium, rocuronium, vecuronium, and pancuronium are safer choices in bronchospastic patients.15 Consider inhaled or IV lidocaine and pre-induction inhaled bronchodilators to blunt airway reactivity.15

Maintenance and bronchodilation

Volatile anesthetics are direct bronchodilators and are the workhorse for maintenance in obstructive disease. In a randomized study of COPD patients undergoing thoracic surgery, both isoflurane and sevoflurane significantly reduced respiratory system resistance, whereas thiopental did not — though a subset of COPD patients did not respond.17 Volatile agents relax airway smooth muscle by altering intracellular calcium signaling and blunt vagal reflex bronchoconstriction, effects independent of β-adrenergic pathways.18,19

Desflurane is the exception: it increases airway resistance and bronchial reactivity and is best avoided in reactive airways.16 Pre-induction inhaled albuterol reduces postoperative bronchospasm and pulmonary infiltration in mild-to-moderate COPD and accelerates sevoflurane wash-in.20

Intraoperative ventilation: managing dynamic hyperinflation and auto-PEEP

This is where COPD physiology dominates management. Because of expiratory flow limitation and prolonged time constants, positive-pressure breaths are delivered before the previous one has fully exhaled. Gas accumulates, end-expiratory lung volume rises above the elastic equilibrium (dynamic hyperinflation), and alveolar pressure remains positive at end-expiration — intrinsic PEEP (auto-PEEP, PEEPi).6,8,9

Auto-PEEP is dangerous on two fronts. Mechanically, it raises peak and plateau airway pressures and predisposes to barotrauma. Hemodynamically, the elevated intrathoracic pressure and lung hyperinflation increase right ventricular afterload, impede venous return, and can cause abrupt hypotension — the classic “breath-stacking” arrest that resolves on brief disconnection from the ventilator.6,9,11 Suspect it whenever a COPD patient becomes hypotensive on the ventilator, and confirm with an expiratory hold or by inspecting the flow tracing (expiratory flow that does not return to zero before the next breath).6,11

The ventilator strategy is aimed squarely at giving the lung time to empty:6

A physiologic refinement: in mechanically ventilated COPD patients, a high-flow inspiratory pattern with an end-inspiratory pause improved CO2 clearance and pH without increasing auto-PEEP, by redistributing inspiratory time toward a plateau while preserving expiratory time.10

Emergence, reversal, and extubation

Residual neuromuscular blockade is a well-established risk factor for postoperative pulmonary complications, and clinical signs (head lift, grip) are insensitive to it. Confirm recovery objectively to a train-of-four ratio ≥0.9 at the adductor pollicis before extubation.25

Sugammadex is the preferred reversal agent for aminosteroid blockade in this population: it reduces residual blockade compared with neostigmine, and observational and meta-analytic data link it to fewer PPCs in at-risk patients (in one cohort, less hypoxemia and atelectasis, but not pneumonia);26,28 in the COPD abdominal-surgery cohort, sugammadex reversal was one of three modifiable factors reducing PPC.7 In the randomized SNaPP trial (3498 adults aged 40 years or older having abdominal or thoracic surgery), postoperative pulmonary complications or death occurred in 19.0% with sugammadex versus 21.5% with neostigmine (risk ratio 0.88, 95% CI 0.77–1.00; p=0.049); the risk reduction was small, with atelectasis of uncertain clinical significance being the most common complication.27 Sugammadex is FDA-approved for reversal of rocuronium- and vecuronium-induced blockade.40

For higher-risk COPD patients, plan the disposition of ventilatory support in advance: extubation directly onto noninvasive ventilation reduces reintubation and postextubation respiratory failure in high-risk groups;29 invasively ventilated patients with a COPD exacerbation are at high risk for extubation failure and in most cases should be extubated to NIV, and in a meta-analysis of 14 RCTs early extubation directly to NIV lowered mortality, ventilator-associated pneumonia, and duration of mechanical ventilation — though this evidence is from ICU weaning rather than postoperative extubation.11

Interscalene block and phrenic nerve palsy

For shoulder and proximal upper-limb surgery, the interscalene brachial plexus block (ISB) is the classic analgesic technique — and the classic hazard in COPD. The phrenic nerve (chiefly C3–C5, C4 predominant) runs on the anterior scalene muscle only about 2 mm anterior to the brachial plexus at the level where the ISB is performed, so local anesthetic spreads readily to it.30,31

Standard ISB causes near-universal ipsilateral phrenic palsy. Hemidiaphragmatic paralysis occurs in 92–100% of patients after a conventional 20 mL interscalene block,31 which can result in a 25% to 32% reduction in the spirometric measures of pulmonary function.39 This is well tolerated in healthy patients but can precipitate dyspnea, hypoxemia, and respiratory failure in patients with severe COPD, obesity, OSA, or limited cardiopulmonary reserve.31,36 For this reason a standard interscalene block is considered a potential contraindication in patients with respiratory compromise, including chronic lung disease, and block choice should be individualized to respiratory reserve.35,38

The paresis is usually transient, resolving with the local anesthetic, but prolonged and even permanent phrenic palsy has been reported, particularly with continuous catheters or intraneural injection.38,39 Adding liposomal bupivacaine to bupivacaine prolongs and deepens the diaphragmatic and pulmonary-function impairment at 24 hours compared with bupivacaine alone.32

Reducing the risk when a block above the clavicle is used

Phrenic-sparing alternatives (risk approaching zero)

Individualize block choice by respiratory reserve. Phrenic-sparing strategies are not universal replacements for ISB: blocks above the clavicle generally give better analgesia but a real phrenic risk, whereas blocks below the clavicle give slightly less complete analgesia with a phrenic risk near zero. In severe COPD, weight the balance decisively toward the distal, phrenic-sparing techniques, and use preoperative and post-block ultrasound assessment of diaphragmatic excursion to detect paresis.35,36

A practical intraoperative checklist

ItemWhy
Defer elective surgery if exacerbating; optimize bronchodilators preoperativelyActive exacerbation and suboptimal control raise PPC risk1,5
Adequate anesthetic depth before laryngoscopy; consider IV/inhaled lidocaineAirway instrumentation triggers bronchospasm15,16
Propofol or ketamine for induction; volatile (sevo/iso) for maintenanceBlunt airway reflexes and bronchodilate14,15,17
Avoid thiopental, atracurium/mivacurium, morphine (histamine)Histamine release and bronchospasm15,24
Tidal volume 6–8 mL/kg IBW, low rate, prolonged expirationReduces dynamic hyperinflation and auto-PEEP6,7
Accept permissive hypercapnia; titrate cautious external PEEPAvoids breath-stacking; offsets auto-PEEP below critical threshold6,8,9
Suspect auto-PEEP if hypotensive on ventilator; disconnect to confirmHyperinflation impairs venous return and RV function6,9,11
Restrict fluidsModifiable factor reducing PPC in COPD7
Confirm TOF ratio ≥0.9; reverse with sugammadexResidual blockade drives PPC; sugammadex reduces PPC7,25,26,28
Plan extubation onto NIV in higher-risk patientsReduces reintubation and postextubation failure in high-risk groups11,29
For shoulder/upper-limb surgery, choose a phrenic-sparing blockStandard ISB causes ~92–100% phrenic palsy, poorly tolerated in COPD31,34

Frequently asked questions

What is the best induction agent for severe COPD?

Propofol or ketamine, because both blunt reflex bronchoconstriction. Propofol produces lower airway resistance after intubation than thiopental or etomidate and reliably suppresses airway reflexes; ketamine (1–2 mg/kg) additionally relaxes airway smooth muscle and supports blood pressure, making it attractive when bronchospasm risk is high or hemodynamics are tenuous.14,15,16,17,41 Thiopental should be avoided because it can provoke bronchospasm and does not reduce airway resistance.15,17

How should a COPD patient be ventilated under general anesthesia?

Give the lung time to empty: low tidal volume (6–8 mL/kg ideal body weight), a reduced respiratory rate, a prolonged expiratory time, and permissive hypercapnia, with cautious external PEEP titrated to counterbalance auto-PEEP without causing further hyperinflation.6,7,8,9 Monitor for dynamic hyperinflation, and if the patient becomes hypotensive on the ventilator, suspect auto-PEEP and briefly disconnect to allow the lungs to deflate.9,11

What is auto-PEEP and why does it matter in COPD?

Auto-PEEP (intrinsic PEEP) is the positive alveolar pressure remaining at end-expiration when expiratory flow limitation prevents the lung from fully emptying before the next breath, causing dynamic hyperinflation.8,9 It raises airway pressures and risk of barotrauma, and by increasing intrathoracic pressure it impairs venous return and right ventricular function, which can cause sudden intraoperative hypotension.6,9

Is an interscalene block safe in a patient with severe COPD?

A standard interscalene block is generally unsafe in severe COPD. It causes ipsilateral phrenic nerve palsy and hemidiaphragmatic paralysis in 92–100% of patients after 20 mL, reducing spirometric measures of pulmonary function by 25% to 32%, which patients with severe COPD may not tolerate.31,39 Choose a phrenic-sparing technique — suprascapular nerve block combined with an infraclavicular or axillary block — or, if a proximal block is required, a low-volume extrafascial injection.33,34,35

Which regional block spares the phrenic nerve for shoulder surgery?

Distal strategies do. A suprascapular nerve block combined with an anterior axillary or infraclavicular block provides true phrenic sparing while preserving shoulder analgesia, reducing hemidiaphragmatic paralysis by roughly 97% (for the combined infraclavicular–suprascapular approach) versus conventional interscalene block in meta-analysis.34,35 Among modifications of the interscalene block itself, low-volume and extrafascial injection reduce but do not eliminate phrenic palsy.33,34

Which neuromuscular reversal agent is preferred in COPD?

Sugammadex, for aminosteroid blockade. It reduces residual neuromuscular blockade compared with neostigmine and is associated with fewer postoperative pulmonary complications in at-risk patients;26,27,28 in a COPD cohort it was one of three modifiable intraoperative factors that lowered PPC risk.7 Confirm a train-of-four ratio ≥0.9 before extubation regardless of the agent used.25

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report (v1.3, 8 Dec 2025). Summarized in: Cazzola M, Bajpai J, Calzetta L, Matera MG, Rogliani P. GOLD 2026: transforming COPD management with early intervention, multi-dimensional assessment, and personalized care. Drugs. 2026. doi:10.1007/s40265-026-02303-3. PMID 41806208.
  2. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242. doi:10.1016/S0140-6736(22)00470-6. PMID 35533707.
  3. Mincham KT, Bruno N, Singanayagam A, Snelgrove RJ. Our evolving view of neutrophils in defining the pathology of chronic lung disease. Immunology. 2021;164(4):701–721. doi:10.1111/imm.13419. PMID 34547115.
  4. Kliment CR, Gurkar AU, Cárdenes N, Ramonell RP, Finkel T, et al. Fueling the fire: metabolic dysfunction and senescence as drivers of lung aging and disease. Physiol Rev. 2026;106(3):1535–1591. doi:10.1152/physrev.00024.2025. PMID 41789983.
  5. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med. 1999;340(12):937–944. doi:10.1056/NEJM199903253401207. PMID 10089188.
  6. Alqahtani JS, Gazwani AY. Intraoperative mechanical ventilation management in COPD: a state of the art review. Clinics (Sao Paulo). 2026;81:101140. doi:10.1016/j.clinsp.2026.101140. PMID 42721777.
  7. Park S, Oh EJ, Han S, Shin B, Shin SH, Im Y, Son YH, Park HY. Intraoperative anesthetic management of patients with chronic obstructive pulmonary disease to decrease the risk of postoperative pulmonary complications after abdominal surgery. J Clin Med. 2020;9(1):150. doi:10.3390/jcm9010150. PMID 31935888.
  8. Rossi A, Brandolese R, Milic-Emili J, Gottfried SB. The role of PEEP in patients with chronic obstructive pulmonary disease during assisted ventilation. Eur Respir J. 1990;3(7):818–822. doi:10.1183/09031936.93.03070818. PMID 2261971.
  9. Ranieri VM, Dambrosio M, Brienza N. Intrinsic PEEP and cardiopulmonary interaction in patients with COPD and acute ventilatory failure. Eur Respir J. 1996;9(6):1283–1292. doi:10.1183/09031936.96.09061283. PMID 8804950.
  10. Pérez J, Dorado JH, Bragagnolo R, Rivera A, Accoce M, et al. End-inspiratory pause enhances ventilation efficiency without increasing autoPEEP in patients with COPD during controlled ventilation. Crit Care. 2026;30(1):185. doi:10.1186/s13054-026-05930-0. PMID 41808206.
  11. Hess DR. Respiratory care management of COPD exacerbations. Respir Care. 2023;68(6):821–837. doi:10.4187/respcare.11069. PMID 37225653.
  12. Kotani Y, Russotto V. Induction agents for tracheal intubation in critically ill patients. Crit Care Med. 2025;53(1):e173–e181. doi:10.1097/CCM.0000000000006506. PMID 39774207.
  13. DeMasi SC, Casey JD, Semler MW. Evidence-based emergency tracheal intubation. Am J Respir Crit Care Med. 2025;211(7):1156–1164. doi:10.1164/rccm.202411-2165CI. PMID 40238943.
  14. Brown RH, Wagner EM. Mechanisms of bronchoprotection by anesthetic induction agents: propofol versus ketamine. Anesthesiology. 1999;90(3):822–828. doi:10.1097/00000542-199903000-00025. PMID 10078684.
  15. Burburan SM, Xisto DG, Rocco PR. Anaesthetic management in asthma. Minerva Anestesiol. 2007;73(6):357–365. PMID 17115010.
  16. Regli A, Sommerfield A, von Ungern-Sternberg BS. Anesthetic considerations in children with asthma. Paediatr Anaesth. 2022;32(2):148–155. doi:10.1111/pan.14373. PMID 34890494.
  17. Volta CA, Alvisi V, Petrini S, Zardi S, Marangoni E, et al. The effect of volatile anesthetics on respiratory system resistance in patients with chronic obstructive pulmonary disease. Anesth Analg. 2005;100(2):348–353. doi:10.1213/01.ANE.0000140240.83236.AC. PMID 15673854.
  18. Moya MAA, Chen L, Otaluka N, Gulluoglu A, Talmor D, et al. Lung protective characteristics of volatile anesthetic sedation. Crit Care. 2026;30(1):274. doi:10.1186/s13054-026-05998-8. PMID 41998735.
  19. Ho GWK, Thaarun T, Ee NJ, Boon TC, Ning KZ, Cove ME, Loh WN. A systematic review on the use of sevoflurane in the management of status asthmaticus in adults. Crit Care. 2024;28(1):334. doi:10.1186/s13054-024-05122-8. PMID 39402635.
  20. Jiang H, Wu X, Lian S, Zhang C, Liu S, Jiang Z. Effects of salbutamol on the kinetics of sevoflurane and the occurrence of early postoperative pulmonary complications in patients with mild-to-moderate COPD. PLoS One. 2021;16(5):e0251795. doi:10.1371/journal.pone.0251795. PMID 34015036.
  21. Jat KR, Chawla D. Ketamine for management of acute exacerbations of asthma in children. Cochrane Database Syst Rev. 2012;11:CD009293. doi:10.1002/14651858.CD009293.pub2. PMID 23152273.
  22. Xu J, Lei H. Ketamine: an update on its clinical uses and abuses. CNS Neurosci Ther. 2014;20(12):1015–1020. doi:10.1111/cns.12363. PMID 25417928.
  23. Rock MJ, Reyes de la Rocha S, L’Hommedieu CS, Truemper E. Use of ketamine in asthmatic children to treat respiratory failure refractory to conventional therapy. Crit Care Med. 1986;14(5):514–516. doi:10.1097/00003246-198605000-00019. PMID 3698618.
  24. Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M, et al. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep. 2018;8(1):11628. doi:10.1038/s41598-018-29965-8. PMID 30072729.
  25. Thilen SR, Weigel WA, Todd MM, Dutton RP, Lien CA, et al. 2023 American Society of Anesthesiologists practice guidelines for monitoring and antagonism of neuromuscular blockade. Anesthesiology. 2023;138(1):13–41. doi:10.1097/ALN.0000000000004379. PMID 36520073.
  26. Aragón-Benedí C, Oliver-Forniés P, Pascual-Bellosta A, Ortega-Lucea SM, et al. Model for predicting early and late-onset postoperative pulmonary complications in perioperative patients receiving neuromuscular blockade: a secondary analysis. Sci Rep. 2023;13(1):5234. doi:10.1038/s41598-023-32017-5. PMID 37002265.
  27. Leslie K, Darvall JN, Chan MTV, Peyton PJ, Myles PS, Corcoran TB, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial. Lancet Respir Med. 2026;14(9):761–774. doi:10.1016/S2213-2600(26)00158-X. PMID 42263720.
  28. Bai YX, Han JJ, Liu J, Li X, Xu ZZ, Lv Y, Liu KX, Wu QP. Sugammadex reduced the incidence of postoperative pulmonary complications in susceptible patients identified by ARISCAT risk index: systematic review and meta-analysis. Adv Ther. 2023;40(9):3784–3803. doi:10.1007/s12325-023-02535-9. PMID 37351811.
  29. Munshi L, Mancebo J, Brochard LJ. Noninvasive respiratory support for adults with acute respiratory failure. N Engl J Med. 2022;387(18):1688–1698. doi:10.1056/NEJMra2204556. PMID 36322846.
  30. Li Q, Chen X, Han J, Xie Y, Gu C. Comparing C3, 4, and 5 nerve root block and interscalene with intermediate cervical plexus block in diaphragmatic motion for clavicle surgery. Sci Rep. 2025;15(1):289. doi:10.1038/s41598-024-80270-z. PMID 39747872.
  31. Yu S, Qian Z, Li E, Han X, Zhao J. Protective effects of C5 level saline injection around the phrenic nerve in interscalene brachial plexus block: a randomized controlled trial. Sci Rep. 2026;16(1):18994. doi:10.1038/s41598-026-50098-w. PMID 42032170.
  32. Berg AA, Flaherty JM, Habeck JM, Harrison AK, Braman JP, et al. Evaluation of diaphragmatic function after interscalene block with liposomal bupivacaine: a randomized controlled trial. Anesthesiology. 2022;136(4):531–541. doi:10.1097/ALN.0000000000004118. PMID 35061005.
  33. Renard Y, Grape S, Gonvers E, Rossel JB, Goetti P, Albrecht E. Respiratory impact of local anaesthetic volume after interscalene brachial plexus block with extrafascial injection: a randomised controlled double-blinded trial. Br J Anaesth. 2025;134(4):1153–1160. doi:10.1016/j.bja.2024.12.010. PMID 39855930.
  34. Oliver-Forniés P, Aragón-Benedí C, Gómez Gómez R, Antón Rodríguez C, et al. Hemidiaphragmatic paralysis after ultrasound-guided brachial plexus blocks for shoulder surgery: a systematic review and meta-analysis of randomized clinical trials. J Clin Anesth. 2025;105:111874. doi:10.1016/j.jclinane.2025.111874. PMID 40494113.
  35. Nanda M, Auyong D. Phrenic-sparing strategies for shoulder surgery: balancing respiratory safety and block completeness. Curr Opin Anaesthesiol. 2026;39(5):641–652. doi:10.1097/ACO.0000000000001682. PMID 42406517.
  36. Spasari E, Cirillo D, Sepolvere G, Ranieri G, Santonastaso D, et al. Regional anesthesia strategies for proximal humerus fracture surgery: anatomical considerations, diaphragm-sparing techniques, and expert perspectives: a narrative review. Langenbecks Arch Surg. 2026;411(1):119. doi:10.1007/s00423-026-03980-0. PMID 41787124.
  37. Hong B, Lee S, Oh C, Park S, Rhim H, et al. Hemidiaphragmatic paralysis following costoclavicular versus supraclavicular brachial plexus block: a randomized controlled trial. Sci Rep. 2021;11(1):18749. doi:10.1038/s41598-021-97843-x. PMID 34548555.
  38. Ahmadzadeh S, Naccari BP, Amedio LS, Koruna AE, Bass D, et al. Efficacy of suprascapular versus interscalene block for post-operative pain management in shoulder surgeries: a narrative review. Curr Pain Headache Rep. 2026;30(1):13 (published online 29 Dec 2025). doi:10.1007/s11916-025-01443-7. PMID 41457137.
  39. Shinn HK, Kim BG, Jung JK, Kwon HU, Yang C, Won J. Prolonged hemidiaphragmatic paresis following continuous interscalene brachial plexus block: a case report. Medicine (Baltimore). 2016;95(24):e3891. doi:10.1097/MD.0000000000003891. PMID 27310984.
  40. Merck Sharp & Dohme LLC. BRIDION (sugammadex) injection, prescribing information (Indications and Usage). Revised 3/2026. DailyMed setid 5171d883-fe8f-482c-97ab-40b00975b64a. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5171d883-fe8f-482c-97ab-40b00975b64a.
  41. Par Health USA, LLC. KETALAR (ketamine hydrochloride) injection, prescribing information (Dosage and Administration). Revised 3/2026. DailyMed setid 14e8f864-8b8a-4e7e-8439-e510d3107063. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e8f864-8b8a-4e7e-8439-e510d3107063.
  42. Hospira, Inc. AMIDATE (etomidate) injection, prescribing information (Dosage and Administration). Revised 04/2022. DailyMed setid b7ed5bf8-ba75-44dc-8f81-96b4ad5766be. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7ed5bf8-ba75-44dc-8f81-96b4ad5766be.

Disclaimer. This page is an educational reference for licensed clinicians. It is not medical advice, does not establish a clinician–patient relationship, and does not substitute for individualized assessment. Anesthetic management must be tailored to the specific patient, COPD severity, procedure, and institutional resources. Much of the perioperative COPD evidence base consists of small studies, physiologic data, and extrapolation from asthma and critical-care populations; verify all drug doses against current package inserts and institutional protocol.

This page was written and cited by the CRNA who builds Helix Anesthesia, a point-of-care reference built for the operating room — surgical cases, drug dosing, regional blocks with labeled ultrasound anatomy, and crisis checklists, all cited and available offline.

The guidance above is cited to the primary literature listed rather than to the app’s own case text. The sourcing standard is the same either way, and it is documented at how we source clinical content.

Built for the anesthesia machine, not the desk. It opens in one tap, works with no signal in an OR that has none, and shows the citation on screen beside the number rather than making you go and find it.

Free tier, no card: every calculator, every crisis checklist, the full drug library and glossary, three complete regional blocks, five complete surgical cases, and 15 AI questions a month.

Get Helix Anesthesia How we source it

Sign up for our newsletter and special offers. New answer pages, improvements to the ones already here, and the occasional offer. Nothing else, and not often.

Physiology under anesthesia

How we source clinical content · All clinical answers